Medicenna Therapeutics (TSE:MDNA) Announces Quarterly Earnings Results

Medicenna Therapeutics (TSE:MDNA) released its earnings results on Thursday. The company reported C($0.05) earnings per share (EPS) for the quarter, FiscalAI reports. Medicenna Therapeutics had a negative return on equity of 103.51% and a negative net margin of 533,640.00%.

Medicenna Therapeutics Stock Down 2.4%

TSE MDNA opened at C$0.41 on Friday. Medicenna Therapeutics has a 12 month low of C$0.38 and a 12 month high of C$1.97. The company has a market capitalization of C$33.79 million, a P/E ratio of -2.70 and a beta of 2.89. The company’s 50 day simple moving average is C$0.50 and its 200 day simple moving average is C$0.74. The company has a debt-to-equity ratio of 3.30, a current ratio of 2.68 and a quick ratio of 4.65.

About Medicenna Therapeutics

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines that specifically target the Interleukin-4 Receptor which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.